-
ASH 2024 | Dr. Mingfeng Zhao: Pursuing Innovation—iCAR-T Therapy Offers New Hope for AML Treatment
Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10,…
-
ASH 2024 | Dr. Wenbin Qian: In-Depth Analysis of Three Key Advances in CAR-T Cell Therapy for Lymphoma
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. Among the highlights of this year’s conference were three oral presentations (Oral 94,…
-
ASH 2024 | Dr. Peihua Lu: Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL
The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10, 2024, in San Diego, showcased cutting-edge advancements in hematology. Among the highlights was a study led by Dr. Peihua Lu from the Beijing Lu Daopei Hematology Hospital, presenting Phase I clinical trial results on CD7 CAR-T cell therapy for relapsed…
-
ASH 2024 | Dr. Sizhou Feng: Improved Preconditioning Regimens and Novel Maintenance Therapies Bring New Momentum to Leukemia Transplantation
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. At this conference, two studies by Dr. Sizhou Feng’s team from the Institute…
-
AASLD Exclusive Interview with Dr. Vincent Wai-Sun Wong: Challenges and Frontiers in Managing MASLD in Asia
Epidemiological Characteristics of MASLD in Asia Hepatology Digest: Could you elaborate on the epidemiological characteristics of MASLD in Asia? How does it differ from other regions? Dr. Vincent Wai-Sun Wong:…
-
Dr. Sizhou Feng’s Team Breakthroughs: Identifying Infection Risk Factors and Optimizing Differential Diagnosis Strategies for Hematological Patients
1. Clinical Characteristics and Risk Factors for 28-Day Mortality in Adult Hematological Patients with Stenotrophomonas maltophilia Bloodstream Infections Stenotrophomonas maltophilia (SM) is a Gram-negative, non-fermentative bacterium known for its ability…
-
ASH 2024 | Dr. Hu Zhou: Exploring the Efficacy and Safety of a Novel SYK Inhibitor in Patients with Relapsed/Refractory ITP
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, drawing global experts and scholars to discuss the latest advancements in hematology. In recent years, increasing insights into the pathogenesis of immune thrombocytopenia (ITP) have paved the way for innovative treatment strategies, among which SYK…
-
ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA, bringing together global experts and scholars in hematology to discuss the latest research developments. At this year’s conference, Dr. Qingqing Cai’s team from Sun Yat-sen University Cancer Center presented two research posters (P3047, P4450),…
Connecting Medical Expertise through Media